A review of current treatment strategies for infective endocarditis.
David Luque PazInes LakbarPierre TattevinPublished in: Expert review of anti-infective therapy (2020)
The use of aminoglycosides for the treatment of endocarditis has been dramatically reduced over the last 20 years. It should be administered once daily, and no longer than 2 weeks. For staphylococcal endocarditis, recent data reinforced the role of anti-staphylococcal penicillins, for methicillin-susceptible isolates (alternative, cefazolin), and vancomycin for methicillin-resistant isolates (alternative, daptomycin). For staphylococcal prosthetic-valve endocarditis, these treatments will be reinforced by the addition of gentamicin during the first 2 weeks, and rifampin throughout the whole treatment duration, i.e. 6 weeks. The optimal duration of antibacterial treatment is 4 weeks for most native valve endocarditis, and 6 weeks for prosthetic-valve endocarditis. The oral switch is safe in patients stabilized after the initial intravenous course.
Keyphrases
- staphylococcus aureus
- methicillin resistant staphylococcus aureus
- aortic valve
- mitral valve
- gestational age
- heart failure
- machine learning
- combination therapy
- aortic stenosis
- newly diagnosed
- high dose
- coronary artery disease
- low dose
- electronic health record
- big data
- transcatheter aortic valve replacement
- preterm birth
- deep learning
- patient reported outcomes
- genetic diversity
- patient reported